• Explore /
  • Poster
  • / A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30‑positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.

A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30‑positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.

Abstract Poster

Authors

null

Cassandra Choe-Juliak

Affimed Inc, NY, NY

Cassandra Choe-Juliak , Karenza M. Alexis , Sylvia Schwarz , Linta Garcia , Ahmed Sawas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

NCT04101331

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3148)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3148

Abstract #

TPS3148

Poster Bd #

212

Abstract Disclosures

Similar Posters

First Author: Andrea Necchi

First Author: Brian T. Hess

First Author: Philippe Armand

First Author: Nancy L. Bartlett